Chiesi, the biopharmaceutical and healthcare group, has announced that the National Institute for Health and Care Excellence (NICE) has recommended Elfabrio (pegunigalsidase alfa) as a treatment for Fabry disease in adults.
BioNTech and Pfizer have received a positive opinion from The Committee for Medicinal Products for Human Use (CHMP) for their updated COVID-19 vaccine, as a single dose for individuals 5 years of age and older, regardless of prior vaccination history,...
Octave Bioscience, a precision care company advancing treatments for multiple sclerosis (MS), has announced the publication of the successful clinical validation of its multiple sclerosis disease activity (MSDA) test in the peer-reviewed journal Clinical...
Cancer immunotherapy, more commonly known as immuno-oncology, continues to gather momentum. As a rapidly evolving field, ongoing research and advancements are coming together to expand the number of available treatments, many of which are showing incredible...
Quest Diagnostics, a provider of diagnostic information services, has announced that its AAVrh74 ELISA assay (CDx) has been granted breakthrough device designation from the U.S. Food and Drug Administration (FDA).
Optibrium, a developer of software and AI solutions for drug discovery, has acquired BioPharmics in a view to expand its 3D drug design and modelling offering.
Lytix Biopharma, a clinical stage immuno-oncology company, has completed recruitment of 20 patients in its trial evaluating LTX-315, the company’s lead drug candidate.
Synthego, a leading provider of industrialized genome editing solutions, and bit.bio, the company coding human cells for novel cures, have expanded their partnership to build a platform centered on the implementation of synthetic circuitry in cells for...
The FDA recently granted approval for Johnson & Johnson’s (J&J) Akeega, a novel first-in-class combination tablet treatment for adults with breast cancer gene (BRCA)-positive, metastatic castration-resistant prostate cancer (mCRPC).
Polpharma Biologics, a biotech company developing and manufacturing biosimilars, has announced that the U.S. Food and Drug Administration (FDA) is the first regulatory body worldwide to approve the use of Tyruko.
A research team led by University of California, Irvine scientists has developed an ‘innovative’ method for quickly creating vast collections of chemical compounds used in drug discovery by using ribosomes, the molecules found in all cells that synthesize...
Janssen, a Johnson & Johnson company, has announced that its bispecific antibody has been granted approval by the European Commission (EC) for use in certain patients with relapsed or refractory multiple myeloma (RRMM).
Actimed Therapeutics Ltd will put some of its additional funding of £4.75 million ($6 million) towards its attempt to provide the world’s first cure for cancer cachexia.
Talus Bioscience, a drug discovery company developing new treatments for cancer, inflammation, and other diseases, has announced $4.3 million in non-dilutive grant funding across three new awards.
MEI Pharma has dosed the first patient in its phase 1 study evaluating ME-344 in combination with bevacizumab (AVASTIN) in patients with previously treated metastatic colorectal cancer.
Genprex has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its lead candidate, Reqorsa immunogene therapy (quaratusugene ozeplasmid), for the treatment of small cell lung cancer (SCLC).
Vaxxinity has announced the publication of its phase 2 clinical trial data for UB-311, stating that the treatment was safe, well-tolerated and demonstrated a trend for slowing cognitive decline in mild Alzheimer's disease (AD).
Digital biomarker company Koneksa has launched the first collaboration in the Koneska Academic Partnership Program for Parkinson’s Disease (KAPP-PD) to incorporate its Neuroscience Toolkit into research programs.
Lonza has launched the Nebula Absorbance Reader, a new absorbance microplate reader, which joins the company’s portfolio of optimized instruments for streamlined endotoxin and pyrogen testing.
Evox Therapeutics, an exosome therapeutics company, has announced the publication of its research identifying novel exosome scaffold proteins that significantly improve drug loading into exosomes for therapeutic purposes.
Terumo Blood and Cell Technologies have announced US Food and Drug Administration (FDA) clearance of the Reveos Automated Whole Blood Processing System.
BlueRock Therapeutics, a clinical stage cell therapy company, and bit.bio, the company coding human cells for novel cures, have announced a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T cells (Tregs)...
Evox Therapeutics, an exosome therapeutics company, has announced a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai in New York, US.
Epsilogen, a leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, has published phase 1 data from the first ever clinical trial of an IgE antibody therapeutic in Nature Communications.
IO Biotech, a clinical-stage biopharma company developing novel, immune-modulating cancer vaccines based on its T-win technology platform, has dosed the first patient in its phase 1 bladder cancer trial.
Boston-based pharma company Ratio Therapeutics has initiated dosing in a phase 1 study evaluating the pharmacokinetics, biodistribution and radiation dosimetry of a novel fibroblast activation protein-alpha (FAP)-targeted radiopharmaceutical, RTX-1363S,...
Gilead Sciences has decided to end a phase 3 trial of magrolimab for higher-risk myelodysplastic syndromes (MDS) after an analysis suggested it would be futile to continue.
PrecisionLife, a computational biology company driving precision medicine in complex chronic diseases, has announced the results of its long COVID study, providing the first detailed genetic insights into the condition and its commonalities with other...
Alnylam Pharmaceuticals has announced positive interim results for the ongoing single ascending dose portion of the phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment...
Science and technology company Merck has announced the expansion of its facility in Lenexa, Kansas, USA, adding 9,100 sq m2 of lab space and production capability to manufacture cell culture media.
Nanjing Iaso Biotherapeutics and Innovent Biologics have received China National Medical Product Administration (NMPA) approval for Fucaso (equecabtagene autoleucel) as a treatment for patients with relapsed or refractory multiple myeloma who have received...
A new genetic sequencing technology from Element Biosciences has helped researchers from the Translational Genomics Research Institute (TGen), part of the City of Hope, identify the likely genetic causes of disorders in six of nine children from Sonora,...
The first and only approved anti-amyloid Alzheimer's Disease (AD) treatment shown to reduce the rate of disease progression and slow cognitive impairment has been granted approval by the FDA.
Meissa Vaccines, a clinical-stage biotech company developing vaccines to prevent viral respiratory infections, has entered into a manufacturing agreement with contract research development organization (CRDMO) Exothera.
Sosei Heptares has dosed the first subject in a phase 1 trial evaluating HTL’149, a first-in-class GPR52 agonist, which represents a novel mechanism of action for the treatment of schizophrenia and related neurological diseases.
Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases, has announced that the first patient has been dosed in its phase 1/2 trial evaluating EO4010.
Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, has closed a $10 million Series A financing round, led by Mercia.
AstraZeneca has shared updated results from a recent phase 3 clinical trial of its Imfinzi (durvalumab) plus Imjudo (tremelimumab) treatment plan in certain patients with hepatocellular carcinoma (HCC), the most common type of liver cancer.
PrecisionLife, a techbio company driving precision medicine in complex chronic diseases, has announced a data access agreement with the University of Oxford to spearhead new treatments for endometriosis.
A microbiome therapeutic developed by the Danish biotech company Freya Biosciences has achieved promising topline results in a phase 1 trial in women with asymptomatic vaginal tract dysbiosis.
Unquestionably, the buzzword of 2023 is artificial intelligence (AI). From ChatGPT-4 preparing to revolutionize online research to IBM’s project debater engaging humans in live debates, it’s clear that we stand at the dawn of a new era of assistive and...
SMi Systems, a company specializing in single molecule imaging and quantification technologies, has disclosed a £6m seed funding round to develop the utility of a novel multi-omic platform for in vitro diagnosis and biomedical research.